ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Sjögren’s syndrome"

  • Abstract Number: PP08 • ACR Convergence 2025

    Living Well Despite the Challenges of Sjögren’s Disease and Systemic Lupus Erythematous: My Perspective as a Health Care Provider and Patient

    Matt Makara, Casey Hogan

    Background/Purpose: Typically, the diagnosis of any autoimmune condition can be challenging and take years. In my case, my diagnosis of Sjögren's disesase (SjD) was established…
  • Abstract Number: 2296 • ACR Convergence 2025

    Evaluation of the Dual Mode of Action of Ianalumab (VAY736) in the Circulation and Salivary Gland Tissue of Patients With Sjögren’s Disease: Results From a Phase 2 Mechanistic Study

    Divi Cornec1, Rainer Hillenbrand2, Patrice Hemon3, Diego Saldana Miranda2, Marion Le Rochais4, Aida Santos Da Costa2, Marie Frutoso3, Cristian Iperi5, Ulrike Sommer2, Arnaud Uguen4, Christophe Jamin4, Patricia Baley6, Caroline Denis6, Dewi Guellec4, Alice Tison4, Daniel Strasser2, sandrine jousse4, Shuqi Chen7, Noemi Giglioli2, CAROLE SIPS2, Alain SARAUX8, Richard Siegel9, Wolfgang Hueber10, Sophie Hillion4, Valerie Devauchelle11 and Claire Bonal2, 1LBAI, UMR1227, University of Brest, CHU Brest, Brest, France, Brest, Bretagne, France, 2Novartis Pharma AG, Basel, Switzerland, Basel, Switzerland, 3LBAI, UMR1227, University of Brest, Brest, France, Brest, France, 4LBAI, UMR1227, University of Brest, CHU Brest, Brest, France, Brest, France, 5LBAI, UMR1227, University of Brest, Brest, France, Basel, France, 6CHU Brest, Brest, France, Brest, France, 7China Novartis Institutes for BioMedical Research, Shanghai, China, Shangai, China (People's Republic), 8CHU Brest, Brest, France, 9Novartis Biomedical Research, Basel, Switzerland, 10Novartis Pharmaceuticals, Basel, Switzerland, 11UBO, Brest, France

    Background/Purpose: Ianalumab, a glycoengineered, fully human, IgG1 mAb directed against B cell-activating factor (BAFF)-receptor (BAFF-R), targets B cells and their functions via a dual mechanism…
  • Abstract Number: 1684 • ACR Convergence 2025

    Integration of Multiple Spatial Transcriptomics Reveals Novel Insights into Sjogren Disease Salivary Gland Fibroblast by Peripheral Serostatus

    Zhou Fang1, Ahmet Coskun1 and Sara McCoy2, 1Georgia Tech, Atlanta, 2University of Wisconsin–Madison, Madison, WI

    Background/Purpose: Anti-SSA antibody positive (SSA+ [Ro52 or Ro60]) and negative (SSA-) Sjögren disease (SjD) have differing clinical phenotypes and prognostic features; however, the pathogenesis driving…
  • Abstract Number: 1397 • ACR Convergence 2025

    Cardiovascular And Cerebrovascular Risk In Sjögren’s Disease: Results From A Prospective Multicenter Cohort.

    Olga Rusinovich1, Zulema Plaza2, Monica Fernandez Castro3, Jose Rosas Gómez de Salazar4, Victor Martinez-Taboada5, Alex Olive6, Raúl Menor Almagro7, Belén Serrano-Benavente8, Judit Font-Urgelles9, Angel Garcia-Aparicio10, Sara Manrique-Arija11, Jesús Alberto Garcia Vadillo12, Ruth Lopez-Gonzalez13, Javier Narváez14, Maria Beatriz Rodriguez15, Carlos Galisteo16, Jorge Juan Gonzalez Martin17, Paloma Vela Casasempere18, Cristina Bohorquez19, MARIA CELIA ERAUSQUIN ARRUABARRENA20, Beatriz Paredes-Romero21, Leyre Riancho-Zarrabeitia22, Sheila Melchor Diaz23, José María Pego-Reigosa24, Sergi Herdia25, Clara Moriano26, Mª Angeles Blazquez Cañamero27, Paula Estrada-Alarcón28, Enrique Judez29, Nerea Alcorta-Lorenzo30, Consuelo Ramos Giraldez31, Fernando Sánchez-Alonso32 and Jose Luis Andreu33, 1Puerta de Hierro University Hospital, Boadilla del Monte, Spain, 2Research Unit, Spanish Society of Rheumatology, Madrid, Spain, Madrid, Spain, 3PUERTA DE HIERRO HOSPITAL, Madrid, Spain, 4Hospital Marina Baixa, PALMA DE MALLORCA, Spain, 5Facultad de Medicina. Universidad de Cantabria, Santander, Spain, 6Solo practice, Barcelona, Spain, 7Department of Rheumatology, Hospital de Jerez, Spain, Puerto De Santa María, Spain, 8Hospital Gregorio Marañon, Madrid, Spain, 9Hospital Universitari Germans Trias i Pujol, Badalona, Spain, 10Hospital Universitario de Toledo, Toledo, Spain, 11Hospital Regional Universitario Málaga, Malaga, Spain, 12Hospital Universitario La Princesa, Madrid, Spain, 13Zamora Health Complex, Salamanca, Spain, 14Hospital Universitario de Bellvitge, Barcelona, Spain, 15Canarias University Hospital, La Laguna- Tenerife, Spain, 16Hospital Parc Taulí, Sabadel, Sabadel, Spain, 17HM Sanchinarro Univeristary Hospital, Madrid, Spain, 18Hospital General Universitario Alicante, Alicante, Comunidad Valenciana, Spain, 19La Paz University Hospital, Alcalá De Henares, Spain, 20Dr Negrin University Hospital, Ls Palmas, Spain, 21Hospital Universitario Infanta Sofía;Universidad Europea de Madrid. Faculty of Medicine, Health and Sports. Department of Medicine; FIIB HUIS-HUHEN, San Sebastian de los Reyes, Spain, 22Rheumatology Department. Hospital Sierrallana, Torrelavega, Spain, 2312 de Octubre University Hospital, Madrid, Spain, 24Department of Rheumatology, University Hospital of Vigo, Vigo, Spain; IRIDIS Group (Investigation in Rheumatology and Immune-Diseases), Galicia Sur Health Research Institute, Vigo, Spain, 25Complex Hospitalari Moisès Broggi, Barcelona, Spain, 26Hospital León, LEON, Castilla y Leon, Spain, 27Hospital Ramon y Cajal, Madrid, Spain, 28Complex Universitari Hospital Moisès Broggi, Barcelona, Spain, 29Albacete University Hospital, Albacete, Spain, 30Rheumatology Department, Donostia University Hospital., San Sebastian, Spain, 31Hospital Universitario Virgen de Valme, Servicio de Reumatología, Seville, Spain, 32Sociedad Española de Reumatología, Madrid, Spain, 33Hospital Universitario Puerta de Hierro, Majadahonda, Spain

    Background/Purpose: To evaluate the incidence of cardiovascular and cerebrovascular events (CVEs) in patients with Sjögren’s Disease (SjD), focusing on major adverse cardiovascular events (MACE), defined…
  • Abstract Number: 1380 • ACR Convergence 2025

    Phenotyping Neuropathic Pain in Sjögren’s Disease: A Cluster-Based Approach

    Beatrice Dei1, Stefano Donati1, Gaetano La Rocca2, Giovanni Fulvio1, Federico Fattorini1, Antonello Sulis1, Michele Moretti1, Elena Elefante1, Francesco Ferro3, Giulia Ricci4, Marta Mosca5 and Chiara Baldini5, 1Rheumatology Unit, University of Pisa, Pisa, Toscana, Italy, 2University of Pisa, Rheumatology Unit, Pisa, Pisa, Italy, 3Clinical and Experimental Medicine Department, Azienda Ospedaliero-Universitaria Pisana, Pisa, Pisa, Italy, 4Neurology Unit, University of Pisa, Pisa, Toscana, Italy, 5University of Pisa, Pisa, Pisa, Italy

    Background/Purpose: Neuropathic pain (NeP) is increasingly recognized as a relevant symptom domain in primary Sjögren’s disease (SjD), contributing to the disease burden beyond glandular involvement.…
  • Abstract Number: 0515 • ACR Convergence 2025

    Inverse Correlation Between Type I Interferon Pathway Activation And Unstimulated Whole Salivary Flow In Sicca Patients

    Nikolaos Marketos1, Charalampos Skarlis1, Sylvia Raftopoulou1, Ada Gjyrezi2, Paul Zumbo3, Doron Betel3, Ioanna E. Stergiou4, Michael Voulgarelis4, Paraskevi Giannakakou5 and Clio Mavragani6, 1Molecular Physiology and Clinical Applications Unit, Department of Physiology, Medical School of Athens, National and Kapodistrian University of Athens, Athens, Greece, Athens, Greece, 2Department of Medicine, Weill Cornell Medicine, New York, NY, USA, and Department of Physiology , National & Kapodistrian University of Athens, Athens, Greece, New York, 3Department of Physiology & Biophysics, Applied Bioinformatics Core, Weill Cornell Medicine, New York, NY, USA, New York, 4Outpatient Rheumatology Clinic, Department of Pathophysiology, Medical School of Athens, National and Kapodistrian University of Athens, Athens, Greece, Athens, Greece, 5Department of Medicine, Weill Cornell Medicine, New York, NY, USA, and Meyer Cancer Center, Weill Cornell Medicine, New York, NY, USA, New York, 6National and Kapodistrian University of Athens, Athens, Greece

    Background/Purpose: Oral and ocular dryness are hallmarks in patients with Sjögren’s disease (SjD). Given that activation of interferon (IFN) pathways has been shown to be…
  • Abstract Number: 2665 • ACR Convergence 2025

    Preexisting Antibodies Against Vaccine Antigens Are Preserved In Patients With Systemic Lupus Erythematosus and Sjögren’s Disease Upon Ianalumab Treatment While Autoantibodies Decline

    Thomas Dörner1, Nan Shen2, Thomas Grader-Beck3, Caroline Walter4, Catherine Wioland4, Celine Rauld4, Patrick Schmutz4, Simone Riek4, Wolfgang Hueber5, CAROLE SIPS6, Stephen Oliver4, Carol Lau7, Claire Bonal6 and Isabelle Isnardi8, 1Charite Universitétsmedizin Berlin, Germany and DRFZ, Berlin, Berlin, Germany, 2Shanghai Jiang Tong University School of Medicine, Shanghai, China (People's Republic), 3Johns Hopkins, Reisterstown, MD, 4Novartis Pharma AG, Basel, Switzerland, 5Novartis Pharmaceuticals, Basel, Switzerland, 6Novartis Pharma AG, Basel, Switzerland, Basel, Switzerland, 7Novartis Pharmaceuticals Corporation, East Hanover, 8Novartis, Gueberschwihr, France

    Background/Purpose: Ianalumab, an afucosylated mAb, depletes B cells via enhanced antibody (Ab)-dependent cellular cytotoxicity and blocks B cell-activating factor (BAFF): BAFF-receptor (BAFF-R) mediated signals.1 It…
  • Abstract Number: 2295 • ACR Convergence 2025

    Autoantibody Profiles and Their Association with Organ Involvement in Primary Sjögren’s Syndrome: Insights from ESSDAI

    Deepak Rath1, Sholen Acharya2 and Dr Alakendu Ghosh3, 1John H Stroger Hospital Jr of Cook County, Chicago, Illinois, USA, 60612, Chicago, IL, 2Department of Reproductive Medicine and Surgery, Government Medical College Thiruvananthapuram, Kerala, India, 695004, Chicago, IL, 3Self employed, Kolkata, West Bengal, India

    Background/Purpose: To evaluate the clinical manifestations, systemic disease activity, and serological profile of patients of Primary Sjögren’s syndrome, and to assess associations between specific autoantibodies…
  • Abstract Number: 1685 • ACR Convergence 2025

    The Sjögren’s Tool for Assessing Response (STAR) demonstrates its ability to accurately detect treatment efficacy in 11 recent RCTs in Sjögren’s disease

    Raphaele Seror1, Gabriel Baron2, Elodie Perrodeau3, Alena Piatrova4, Hendrika Bootsma5, Simon Bowman6, Jacques-eric GOTTENBERG7, Divi Cornec8, michele Bombardieri9, Suzanne Arends10, Benjamin A. Fisher11, Wolfgang Hueber12, Antoine Sreih13, Antonia Christodoulou14, Andre van Maurik15, Joel van Roon16, Valerie Devauchelle17, Peter Gergely18, Xavier Mariette19 and Raphael Porcher20, 1Department of Rheumatology, National referral center for auto immune disease and Sjogren disease, Université Paris-Saclay, INSERM UMR1184: Centre for Immunology of Viral Infections and Autoimmune Diseases, Assistance Publique-Hôpitaux de Paris, Hôpital Bicêtre, Le Kremlin Bicêtre, Paris, France., le kremlin bicetre, France, 2Hôtel-Dieu, Université Paris Cité,, Paris, France, 3Université Paris Descartes Sorbonne Paris Cité, Paris, France, 4Department of Rheumatology, National referral center for auto immune disease and Sjogren disease, Université Paris-Saclay, INSERM UMR1184: Centre for Immunology of Viral Infections and Autoimmune Diseases, Assistance Publique-Hôpitaux de Paris, Hôpital Bicêtre, Le Kremlin Bicêtre, Paris, France., Paris, Ile-de-France, France, 5UMCG, Groningen, Netherlands, 6University Hospitals Birmingham, Birmingham, United Kingdom, 7Hautepierre Hospital, STRASBOURG, Alsace, France, 8Departement of Rhumatology, CHU Brest, Université de Brest, INSERM UMR1227: LBAI, Brest, France, Brest, France, 9Experimental Medicine and Rheumatology, William Harvey Research Institute, Queen Mary University of London, UK, London, United Kingdom, 10University Medical Center Groningen, Groningen, Netherlands, 11King’s College London, London, UK; Institute of Inflammation and Ageing, University of Birmingham, Birmingham, UK, Birmingham, United Kingdom, 12Novartis Pharmaceuticals, Basel, Switzerland, 13Cullinan Therapeutics, New York, NY, 14BMS, Princeton, NJ, 15GlaxoSmithKline, Stevenage, United Kingdom, 16Center of Translational Immunology, Department of Immunology and Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht University, Utrecht PO BOX 85500, 3508 GA, Netherlands, Utrecht, Netherlands, 17UBO, Brest, France, 18Novartis Biomedical Research, Basel, Switzerland, 19Université Paris-Saclay, Le Kremlin Bicetre, France, 20Université Paris Cité and Université Sorbonne Paris Nord, INSERM, INRAE, Center for Research in Epidemiology and StatisticS (CRESS), Paris, France, Paris, France

    Background/Purpose: Performance of the recently developed composite responder index STAR is highly awaited. We conduscted this study to evaluate the performance of STAR in previously…
  • Abstract Number: 1395 • ACR Convergence 2025

    A Comparative Study of Yao Syndrome and Primary Sjögren’s Syndrome

    Nayaab Bakshi1, Christopher Loh2, Song Wu3 and Qingping Yao3, 1Stony Brook University, Dix Hills, NY, 2Stony Brook University, Lake Grove, NY, 3Stony Brook University, Stony Brook, NY

    Background/Purpose: Yao syndrome (YAOS, OMIM 617321) is formerly named Nucleotide-binding oligomerization domain containing protein 2 (NOD2)-associated autoinflammatory disease affecting multiorgan systems characterized by recurrent fever,…
  • Abstract Number: 1378 • ACR Convergence 2025

    Prevalence of Central Nervous System Manifestations in Sjögren’s Disease

    Arun Varadhachary1, Ghaith Noaiseh2, Katherine Hammitt3, Julie Frantsve-Hawley3, Paula Barreras Cortes4, Shamik Bhattacharyya5, E. Sherwood Brown6, Drew Carey7, Robert Fox8, Brent Goodman9, Thomas Grader-Beck10, Janet Lewis11, Stephen Maitz12, Steven Mandel13, Jenifer McCombe14, Astrid Rasmussen15, George Sarka16, Daniel Wallace17, Frederick Vivino18, Rochelle Zak19, Nancy Carteron20, R Hal Scofield15 and Steven Carsons21, 1Washington University in St. Louis, St. Louis, MO, 2University of Kansas Medical Center, Kansas City, KS, 3Sjogren's Foundation, Reston, VA, 4Cedars Sinai, Los Angeles, CA, 5Brigham and Women's Hospital, Malden, MA, 6UT Southwestern Medical Center, Dallas, TX, 7Johns Hopkins University School of Medicine, Baltimore, MD, 8Rheumatology Clinic, San Diego, CA, 9HonorHealth, Scottsdale, AZ, 10Johns Hopkins, Reisterstown, MD, 11University of Virginia, Charlottesville, VA, 12U.S. Department of Veterans Affairs, Coatesville, PA, 13Donald and Barbara Zucker School of Medicine and Hofstra/Northwell, Hempstead, NY, 14University of Alberta, Edmonton, AB, Canada, 15Oklahoma Medical Research Foundation, Oklahoma City, OK, 16Cedars-Sinai Medical Center, Laguna Hills, CA, 17Cedars Sinai Medical Center, Studio City, CA, 18University of Pennsylvania, Bryn Mawr, PA, 19UCSF Health, San Francisco, CA, 20University of California, Berkeley & San Francisco, Angwin, CA, 21NYU Long Island School of Medicine, Mineola, NY

    Background/Purpose: Sjögren’s disease is a systemic autoimmune disorder with diverse clinical manifestations affecting multiple organ systems. While dry mouth, dry eyes, fatigue and pain are…
  • Abstract Number: 0516 • ACR Convergence 2025

    Association between anti-cytosolic 5′-nucleotidase 1A (anti-cN1A) antibodies and lymphoma in primary Sjögren Disease (SD)

    Pierre-Marie Duret1, Maude Bouchard-Marmen2, Loukas Chatzis3, Margherita Giannini4, François Severac5, FELTEN Renaud6, Dan Levy7, Benoit Nespola8, Emmanuel Chatelus9, Emmanuelle Dernis10, Valerie Devauchelle11, Philippe Dieude12, Jean-Jacques Dubost13, Anne-Laure Fauchais14, Bernard Geny15, Eric Hachulla16, Claire larroche17, Véronique Le Guern18, Jacques Morel19, Aleth Perdriger20, Carine Salliot21, Alain SARAUX22, Damien Sène23, Jean Sibilia24, SORDET Christelle6, Olivier Vittecoq25, Raphaele Seror26, Gaetane Nocturne27, Andreas Goules28, Athanasios G. Tzioufas29, Xavier Mariette30, Jacques-eric GOTTENBERG31 and Alain Meyer32, 1Colmar General Hospital; Strasbourg University Hospital, Strasbourg, France, 2CHU de Québec, Québec, QC, Canada, 3Pathophysiology Department, Athens School of Medicine, National and Kapodistrian University of Athens, Greece, Athens, Greece, 4Explorations fonctionnelles musculaires, Service de physiologie, Hôpitaux Universitaires de Strasbourg, Strasbourg, Service de Rhumatologie, Centre de référence des maladies auto-immunes rares (RESO), Hôpitaux Universitaires de Strasbourg, Strasbourg, Strasbourg, Alsace, France, 5Département de Santé Publique, Groupe Méthodes en Recherche Clinique (GMRC), CHU de Strasbourg, Strasbourg, Strasbourg, Alsace, France, 6Service de Rhumatologie, Centre de référence des maladies auto-immunes rares (RESO), Hôpitaux Universitaires de Strasbourg, Strasbourg, Strasbourg, Alsace, France, 7Explorations fonctionnelles musculaires, Service de physiologie, Hôpitaux Universitaires de Strasbourg, Strasbourg, Strasbourg, Alsace, France, 8Laboratoire d’Immunologie, Hôpitaux Universitaires de Strasbourg, Strasbourg, Strasbourg, Alsace, France, 9Department of Rheumatology, University Hospital Strasbourg, France, Strasbourg, France, 10Service de Rhumatologie, Centre Hospitalier Le Mans, Le Mans, Le Mans, France, 11UBO, Brest, France, 12Service de Rhumatologie, Hôpital Bichat APHP, Paris, Paris, Ile-de-France, France, 13Service de Rhumatologie, CHU Gabriel Montpied, Clermont-Ferrand, Clermont-Ferrand, France, 14UR 3072, Centre de Recherche en Biomédecine, Université de Strasbourg, Strasbourg; France, Strasbourg, France, 15UR 3072, Centre de Recherche en Biomédecine, Université de Strasbourg, Strasbourg; FranceExplorations fonctionnelles musculaires, Service de physiologie, Hôpitaux Universitaires de Strasbourg, Strasbourg;, Strasbourg, Alsace, France, 16Service de Médecine Interne et Immunologie Clinique, CHU de Lille, Hôpital Claude Huriez, Lille, Lille, France, 17Service de Médecine Interne, Hôpital Avicenne APHP, Bobigny, Paris, Ile-de-France, France, 18Cochin hospital, Paris, France, 19CHU and University of Montpellier, Montpellier, France, 20Rennes University, Rennes, France, 21CHR orleans, Orleans, France, 22CHU Brest, Brest, France, 23Department of Internal Medicine, Lariboisière University Hospital, Université Paris Cité, Assistance Publique Hôpitaux de Paris, Paris, Ile-de-France, France, 24Rheumatology Department, National Center for Rare autoimmune disease RESO,Strasbourg University Hospital, Strasbourg, Alsace, France, 25Service de Rhumatologie & CIC-CRB 1404, CHU de Rouen, Université de Rouen, Rouen, Rouen, France, 26Department of Rheumatology, National referral center for auto immune disease and Sjogren disease, Université Paris-Saclay, INSERM UMR1184: Centre for Immunology of Viral Infections and Autoimmune Diseases, Assistance Publique-Hôpitaux de Paris, Hôpital Bicêtre, Le Kremlin Bicêtre, Paris, France., le kremlin bicetre, France, 27University Paris Saclay, Le Kremlin Bicetre, Ile-de-France, France, 28Department of Pathophysiology, School of Medicine, National and Kapodistrian University of Athens Institute for Autoimmune Systemic and Neurologic Diseases, Athens, Athens, Greece, 29Department of Pathophysiology, School of Medicine, National and Kapodistrian University of Athens Institute for Autoimmune Systemic and Neurologic Diseases, Athens, Athens, 30Université Paris-Saclay, Le Kremlin Bicetre, France, 31Hautepierre Hospital, STRASBOURG, Alsace, France, 32Service de Rhumatologie, Centre de référence des maladies auto-immunes rares (RESO), Hôpitaux Universitaires de Strasbourg, Strasbourg, Explorations fonctionnelles musculaires, Service de physiologie, Hôpitaux Universitaires de Strasbourg, Strasbourg, UR 3072, Centre de Recherche en Biomédecine, Université de Strasbourg, Strasbourg; France, Strasbourg, Alsace, France

    Background/Purpose: There is an unmet clinical need for identification of novel biomarkers of systemic complications and lymphoma in primary Sjögren disease (SD). Anti-cytosolic 5'-nucleotidase 1A…
  • Abstract Number: 2499 • ACR Convergence 2025

    Concomitant Anti-Ro/SSA Antibodies in Systemic Sclerosis Patients is Associated with Risks Beyond Dryness

    Rachael Gordon1, Leah Wunsch2, Maureen Lauffoon1, Thomas Medsger, Jr3 and Robyn Domsic1, 1University of Pittsburgh, Pittsburgh, PA, 2University of Pittsburgh, Pittsburgh, 3Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, Verona, PA

    Background/Purpose: Sjogren’s disease (SjD) is a common systemic autoimmune disorder characterized by progressive inflammation of the exocrine glands, resulting in dry eyes and dry mouth.…
  • Abstract Number: 2294 • ACR Convergence 2025

    Comparative Analysis of Patients Included in Trials Utilizing Biologic Drugs in the Treatment of Primary Sjögren’s Syndrome

    Carlota Navarro Joven1, Silvia Piunno2, Maryia Nikitsina3, CARMEN SAN JOSE MENDEZ4 and David A. Isenberg5, 1Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain, 2Fondazione Policlinico Universitario Agostino Gemelli, Rome, Italy, 3University Hospital La Princesa, Madrid, Madrid, Madrid, Spain, 4Complejo Hospitalario Universitario de A Coruña (CHUAC), A Coruña, Spain, 5University College London, London, United Kingdom

    Background/Purpose: Sjögren’s syndrome is a heterogeneous autoimmune disease with no approved disease-modifying treatments. The aim of this systematic review was to evaluate primary Sjögren’s syndrome…
  • Abstract Number: 1683 • ACR Convergence 2025

    Serum APRIL Is Associated With B-Cell Activation Markers, Disease Activity, and Lymphoma Risk in Sjögren Disease (SD): Data From the prospective ASSESS Cohort

    Pierre-Marie Duret1, Pascal Schneider2, Ludivine Robin3, Marine Vierling4, Nicolas Meyer5, Valerie Devauchelle6, Divi Cornec7, Alain SARAUX8, Jean Sibilia9, Raphaele Seror10, Yann Nguyen11, Gaetane Nocturne12, Laurent Mauvieux13, Laurent Miguet14, Xavier Mariette15 and Jacques-eric GOTTENBERG16, 1Colmar General Hospital; Strasbourg University Hospital, Strasbourg, France, 2Université de Lausanne,Département de biochimie, Lausanne, Switzerland, 3Strasbourg University Hospital, Department of pathology, 4CNRS, Immunopathologie et Chimie Thérapeutique/Laboratory of Excellence Medalis, Institut de Biologie Moléculaire et Cellulaire (IBMC), Strasbourg, France Strasbourg, France;, Strasbourg, Alsace, France, 4Strasbourg University Hospital, Department of Public Health, GMRC, Strasbourg, France,, Strasbourg, Alsace, France, 5Strasbourg University Hospital, Department of Public Health, GMRC, Strasbourg, France, Strasbourg, Alsace, France, 6UBO, Brest, France, 7LBAI, UMR1227, University of Brest, CHU Brest, Brest, France, Brest, Bretagne, France, 8CHU Brest, Brest, France, 9Rheumatology Department, National Center for Rare autoimmune disease RESO,Strasbourg University Hospital, Strasbourg, Alsace, France, 10Department of Rheumatology, National referral center for auto immune disease and Sjogren disease, Université Paris-Saclay, INSERM UMR1184: Centre for Immunology of Viral Infections and Autoimmune Diseases, Assistance Publique-Hôpitaux de Paris, Hôpital Bicêtre, Le Kremlin Bicêtre, Paris, France., le kremlin bicetre, France, 11Department of Internal Medicine, Beaujon Hospital, AP-HP Nord, Université Paris Cité, Clichy, France, Clichy, France, 12University Paris Saclay, Le Kremlin Bicetre, Ile-de-France, France, 13Strasbourg University Hospital, Laboratory hematology, Strasbourg, France,CNRS, Immunopathologie et Chimie Thérapeutique/Laboratory of Excellence Medalis, Institut de Biologie Moléculaire et Cellulaire (IBMC), Strasbourg, France, Strasbourg, Alsace, France, 14Strasbourg University Hospital, Laboratory hematology, Strasbourg, France, CNRS, Immunopathologie et Chimie Thérapeutique/Laboratory of Excellence Medalis, Institut de Biologie Moléculaire et Cellulaire (IBMC), Strasbourg, France, Strasbourg, Alsace, France, 15Université Paris-Saclay, Le Kremlin Bicetre, France, 16Hautepierre Hospital, STRASBOURG, Alsace, France

    Background/Purpose: Sjögren disease (SD) is a B cell driven systemic auto-immune disease, with a need for biomarkers to better assess disease activity, risk of lymphoma…
  • 1
  • 2
  • 3
  • …
  • 24
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology